Children born with uncontrolled tissue overgrowth have spent decades without a single approved therapy. That changed at the European Medicines Agency’s May meeting, where the Committee for Medicinal Products for Human Use cleared eight new medicines for the bloc and recommended widening the uses of thirteen others already on pharmacy shelves.
The headline name is Vijoice, the brand for alpelisib from Novartis. Reviewers granted it a conditional marketing authorisation for severe PIK3CA-related overgrowth spectrum, a cluster of rare genetic conditions that drive abnormal growth of tissue, producing disfiguring malformations and tumours. It is the first medicine the agency has ever backed for the disorder, and for the families affected the practical meaning is simple: a treatment route exists where none did before. The conditional label matters too. It signals that the committee accepted a smaller evidence base in exchange for early access, with the obligation to supply fuller trial data later.
Lung specialists drew their own conclusion from the same session. Jascayd, the Boehringer Ingelheim drug built around nerandomilast, won a positive opinion for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, two conditions defined by relentless, irreversible scarring of lung tissue. The pipeline for fibrosis has been thin for years, and a fresh mechanism reaching patients changes the calculus for clinicians who currently have few tools to slow the disease.
Oncology featured as well. The committee adopted a favourable view of Etcamah, the AstraZeneca oral therapy based on camizestrant, for adults with advanced or metastatic breast cancer carrying an ESR1 mutation. That mutation is one of the ways tumours learn to dodge standard hormone therapy, so a drug aimed squarely at it addresses a well-documented gap rather than crowding an already busy field.
A positive opinion is a recommendation, not a licence. The files now travel to the European Commission, which issues the marketing authorisation valid across all member states, usually within roughly two months. National pricing and reimbursement talks follow, and those determine when a patient in any given country can actually collect a prescription. The lag between a committee verdict and a filled box can stretch well beyond a year in some markets, a reminder that approval is a milestone rather than a finish line.
What ties the batch together is the weighting toward rare and hard-to-treat conditions. A first-ever therapy for an orphan disorder, a new option for fibrosis, and a targeted answer to treatment resistance in cancer all point at a regulator increasingly comfortable acting on narrower evidence when the unmet need is acute. That posture rewards companies willing to chase small patient populations, and it shifts more of the verification work into the post-approval period, where real-world performance and follow-up studies carry the burden of proof.
For patients and the clinicians who treat them, the month delivered something concrete: several doors that were shut are now, at least procedurally, open. The next test is whether national health systems move quickly enough to make those openings count, because a recommendation that stalls in pricing negotiations helps no one waiting for it.
